KR20110071103A - 방출 제어 의약 조성물 - Google Patents
방출 제어 의약 조성물 Download PDFInfo
- Publication number
- KR20110071103A KR20110071103A KR1020117009897A KR20117009897A KR20110071103A KR 20110071103 A KR20110071103 A KR 20110071103A KR 1020117009897 A KR1020117009897 A KR 1020117009897A KR 20117009897 A KR20117009897 A KR 20117009897A KR 20110071103 A KR20110071103 A KR 20110071103A
- Authority
- KR
- South Korea
- Prior art keywords
- controlled release
- pharmaceutical composition
- release pharmaceutical
- formulation
- composition according
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (19)
- (1) (R)-2-(2-아미노티아졸-4-일)-4'-[2-[(2-히드록시-2-페닐에틸)아미노]에틸]아세트산아닐리드 또는 그의 제약학적으로 허용되는 염, (2) 1 g을 용해하는 물의 양이 10 mL 이하인 용해성을 나타내는 제제 내부에 물을 침입시키기 위한 1종 이상의 첨가제, 및 (3) 평균 분자량이 약 10만 이상, 또는 5% 수용액 25 ℃의 점도가 12 mPaㆍs 이상인 하이드로겔을 형성하는 고분자 물질을 함유하여 이루어지는 방출 제어 의약 조성물.
- 제1항에 있어서, 제제 내부에 물을 침입시키기 위한 첨가제가 폴리에틸렌글리콜, 폴리비닐피롤리돈, D-만니톨, D-소르비톨, 자일리톨, 젖당, 백당, 무수 말토오스, D-프럭토오스, 덱스트란, 포도당, 폴리옥시에틸렌 경화 피마자유, 폴리옥시에틸렌폴리옥시프로필렌글리콜, 폴리옥시에틸렌소르비탄 고급 지방산 에스테르, 염화나트륨, 염화마그네슘, 시트르산, 타르타르산, 글리신, β-알라닌, 염산리신 및 메글루민으로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 방출 제어 의약 조성물.
- 제2항에 있어서, 제제 내부에 물을 침입시키기 위한 첨가제가 폴리에틸렌글리콜, 폴리비닐피롤리돈, D-만니톨, 젖당, 백당, 염화나트륨 및 폴리옥시에틸렌폴리옥시프로필렌글리콜로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 방출 제어 의약 조성물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 제제 내부에 물을 침입시키기 위한 첨가제의 양이 제제 전체의 중량에 대하여 5 중량% 이상 75 중량% 이하인 방출 제어 의약 조성물.
- 제4항에 있어서, 제제 내부에 물을 침입시키기 위한 첨가제의 양이 제제 전체의 중량에 대하여 5 중량% 이상 70 중량% 이하인 방출 제어 의약 조성물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 하이드로겔을 형성하는 고분자 물질이 폴리에틸렌옥시드, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스나트륨, 히드록시에틸셀룰로오스 및 카르복시비닐 중합체로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 방출 제어 의약 조성물.
- 제6항에 있어서, 하이드로겔을 형성하는 고분자 물질이 폴리에틸렌옥시드, 히드록시프로필메틸셀룰로오스 및 히드록시프로필셀룰로오스로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 방출 제어 의약 조성물.
- 제1항 내지 제7항 중 어느 한 항에 있어서, 하이드로겔을 형성하는 고분자 물질의 양이 제제 전체의 중량에 대하여 1 중량% 이상 70 중량% 이하인 방출 제어 의약 조성물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 항산화제를 추가로 함유하여 이루어지는 방출 제어 의약 조성물.
- 제9항에 있어서, 항산화제가 부틸히드록시톨루엔, 갈산프로필 및 아스코르브산나트륨으로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 방출 제어 의약 조성물.
- 제10항에 있어서, 항산화제가 부틸히드록시톨루엔인 방출 제어 의약 조성물.
- 제9항 내지 제11항 중 어느 한 항에 있어서, 항산화제의 배합량이 0.025 중량% 이상 0.25 중량% 이하인 방출 제어 의약 조성물.
- 제1항 내지 제12항 중 어느 한 항에 있어서, 안정화제를 추가로 함유하여 이루어지는 방출 제어 의약 조성물.
- 제13항에 있어서, 안정화제가 황색 32 산화철, 적색 32 산화철 및 흑색 산화철로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 방출 제어 의약 조성물.
- 제14항에 있어서, 안정화제가 황색 32 산화철 및/또는 적색 32 산화철인 방출 제어 의약 조성물.
- 제13항 내지 제15항 중 어느 한 항에 있어서, 안정화제의 배합량이 0.05 중량% 이상 1 중량% 이하인 방출 제어 의약 조성물.
- (1) (R)-2-(2-아미노티아졸-4-일)-4'-[2-[(2-히드록시-2-페닐에틸)아미노]에틸]아세트산아닐리드 또는 그의 제약학적으로 허용되는 염에, (2) 1 g을 용해하는 물의 양이 10 mL 이하인 용해성을 나타내는 제제 내부에 물을 침입시키기 위한 1종 이상의 첨가제를 제제 전체에 대하여 5% 이상 75% 이하, 및 (3) 평균 분자량이 약 10만 이상, 또는 5% 수용액 25 ℃의 점도가 12 mPaㆍs 이상인 하이드로겔을 형성하는 고분자 물질을 제제 전체의 중량에 대하여 1 중량% 이상 70 중량% 이하를 배합하는 것을 특징으로 하는 방출 제어 의약 조성물의 제조 방법.
- 제17항에 있어서, 제제 내부에 물을 침입시키기 위한 첨가제가 폴리에틸렌글리콜, 폴리비닐피롤리돈, D-만니톨, D-소르비톨, 자일리톨, 젖당, 백당, 무수 말토오스, D-프럭토오스, 덱스트란, 포도당, 폴리옥시에틸렌 경화 피마자유, 폴리옥시에틸렌폴리옥시프로필렌글리콜, 폴리옥시에틸렌소르비탄 고급 지방산 에스테르, 염화나트륨, 염화마그네슘, 시트르산, 타르타르산, 글리신, β-알라닌, 염산리신 및 메글루민으로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 방출 제어 의약 조성물의 제조 방법.
- 제17항 또는 제18항에 있어서, 하이드로겔을 형성하는 고분자 물질이 폴리에틸렌옥시드, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스나트륨, 히드록시에틸셀룰로오스 및 카르복시비닐 중합체로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 방출 제어 의약 조성물의 제조 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10133808P | 2008-09-30 | 2008-09-30 | |
US61/101,338 | 2008-09-30 | ||
PCT/JP2009/066742 WO2010038690A1 (ja) | 2008-09-30 | 2009-09-28 | 放出制御医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110071103A true KR20110071103A (ko) | 2011-06-28 |
KR101524164B1 KR101524164B1 (ko) | 2015-06-01 |
Family
ID=42073454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117009897A KR101524164B1 (ko) | 2008-09-30 | 2009-09-28 | 방출 제어 의약 조성물 |
Country Status (24)
Country | Link |
---|---|
US (3) | US20160184275A2 (ko) |
EP (2) | EP2345410B1 (ko) |
JP (2) | JP4688089B2 (ko) |
KR (1) | KR101524164B1 (ko) |
CN (2) | CN105232448A (ko) |
AU (1) | AU2009300752C1 (ko) |
BR (1) | BRPI0919466B1 (ko) |
CA (1) | CA2740342C (ko) |
CY (1) | CY1123724T1 (ko) |
DK (1) | DK2345410T3 (ko) |
ES (1) | ES2847876T3 (ko) |
HK (1) | HK1216232A1 (ko) |
HR (1) | HRP20210179T1 (ko) |
HU (1) | HUE052874T2 (ko) |
IL (1) | IL212033A (ko) |
LT (1) | LT2345410T (ko) |
MX (1) | MX351855B (ko) |
PL (1) | PL2345410T3 (ko) |
PT (1) | PT2345410T (ko) |
RU (1) | RU2495666C2 (ko) |
SI (1) | SI2345410T1 (ko) |
TW (1) | TWI478712B (ko) |
WO (1) | WO2010038690A1 (ko) |
ZA (1) | ZA201102406B (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190117072A (ko) | 2018-04-06 | 2019-10-16 | 한미약품 주식회사 | 미라베그론이 함유된 방출 제어 약학적 조성물 |
KR20200043715A (ko) | 2018-10-18 | 2020-04-28 | 한미약품 주식회사 | 미라베그론이 함유된 방출 제어 약제학적 조성물 |
KR20210001710A (ko) | 2019-06-28 | 2021-01-06 | 한미약품 주식회사 | 제어 방출형 미라베그론 제제 및 이의 제조방법 |
KR20210112240A (ko) * | 2020-03-03 | 2021-09-14 | 동광제약 주식회사 | 미라베그론을 포함하는 제어 방출 제제 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ291495B6 (cs) * | 1992-09-18 | 2003-03-12 | Yamanouchi Pharmaceutical Co., Ltd. | Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním |
TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
WO2011122523A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 放出制御医薬組成物 |
ES2665467T3 (es) * | 2010-03-29 | 2018-04-25 | Astellas Pharma Inc. | Composición farmacéutica de liberación modificada |
WO2012030927A2 (en) * | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
US9907789B2 (en) * | 2011-10-21 | 2018-03-06 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
JP6123795B2 (ja) * | 2012-03-30 | 2017-05-10 | アステラス製薬株式会社 | 放出制御医薬組成物 |
EP2832730A4 (en) | 2012-03-30 | 2015-09-09 | Astellas Pharma Inc | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION |
EA201590449A1 (ru) * | 2012-08-31 | 2015-06-30 | Астеллас Фарма Инк. | Перорально вводимая лекарственная композиция |
JP2017078023A (ja) * | 2014-02-28 | 2017-04-27 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
CN104523635B (zh) * | 2014-12-23 | 2017-05-03 | 深圳万乐药业有限公司 | 米拉贝隆缓释药物组合物 |
JP2018090490A (ja) | 2015-03-31 | 2018-06-14 | アステラス製薬株式会社 | ミラベグロン含有医薬組成物 |
JP6618736B2 (ja) * | 2015-09-01 | 2019-12-11 | 沢井製薬株式会社 | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 |
EP3448366A1 (en) | 2016-04-25 | 2019-03-06 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
EP3448367A1 (en) | 2016-04-25 | 2019-03-06 | Synthon BV | Tablets comprising mirabegron and solifenacin |
EP3360866B1 (en) | 2017-02-14 | 2019-01-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Mirabegron prodrugs |
KR102051132B1 (ko) * | 2017-03-17 | 2019-12-02 | 주식회사 종근당 | 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물 |
KR20170088783A (ko) * | 2017-07-07 | 2017-08-02 | 지엘팜텍주식회사 | 미라베그론의 습식과립 조성물 |
WO2019013583A2 (ko) | 2017-07-14 | 2019-01-17 | 주식회사 대웅제약 | 약제학적 제제 및 그 제조방법 |
KR101937713B1 (ko) * | 2017-07-14 | 2019-01-14 | 주식회사 대웅제약 | 약제학적 제제 및 그 제조방법 |
EP3292864A1 (en) * | 2017-10-12 | 2018-03-14 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
EP3694492A1 (en) * | 2017-10-12 | 2020-08-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
US10478399B2 (en) | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
KR20190089758A (ko) | 2018-01-22 | 2019-07-31 | (주)동구바이오제약 | 미라베그론 또는 이의 약제학적으로 허용가능한 염을 함유하는 지속 방출 제제 |
KR102062791B1 (ko) | 2019-02-26 | 2020-01-06 | 신일제약 주식회사 | 미라베그론 또는 그의 약제학적으로 허용되는 염을 함유한 방출조절 제제 |
AR121207A1 (es) * | 2020-01-31 | 2022-04-27 | Nippon Shinyaku Co Ltd | Composición de liberación controlada |
CN113662922A (zh) * | 2020-10-29 | 2021-11-19 | 北京莱瑞森医药科技有限公司 | 一种米拉贝隆缓释组合物及其制备方法和应用 |
CN114306262B (zh) * | 2021-12-30 | 2023-09-05 | 乐泰药业有限公司 | 米拉贝隆缓释片及其制备方法和质量检测方法 |
EP4338729A1 (en) * | 2022-09-19 | 2024-03-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A tablet comprising mirabegron |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
CZ291495B6 (cs) | 1992-09-18 | 2003-03-12 | Yamanouchi Pharmaceutical Co., Ltd. | Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním |
SK279684B6 (sk) | 1993-06-14 | 1999-02-11 | Janssen Pharmaceutica N.V. | Tableta a spôsob jej výroby |
DK1014941T3 (da) | 1996-06-26 | 2009-07-27 | Univ Texas | Ekstruderbar farmaceutisk hot-melt-formulering |
US6204285B1 (en) | 1996-07-01 | 2001-03-20 | Sepracor Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate |
AU731391B2 (en) | 1996-08-19 | 2001-03-29 | Kissei Pharmaceutical Co. Ltd. | Drug for the prevention or treatment of pollakiuria and urinary incontinence |
US6630515B2 (en) | 1997-08-28 | 2003-10-07 | Afferon Corporation | Urinary incontinence therapy |
BR9804500B1 (pt) | 1997-10-17 | 2010-06-15 | derivado de amida, referida composição farmacêutica e agente terapêutico. | |
WO1999031045A1 (fr) | 1997-12-18 | 1999-06-24 | Kissei Pharmaceutical Co., Ltd. | Derives d'acide phenylaminoalkylcarboxylique et compositions medicamenteuses les contenant |
ATE275126T1 (de) | 1998-04-14 | 2004-09-15 | Kissei Pharmaceutical | 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen |
MY126489A (en) | 1998-07-08 | 2006-10-31 | Kissei Pharmaceutical | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
MXPA02001267A (es) | 1999-08-04 | 2002-08-12 | Yamanouchi Pharma Co Ltd | Composicion farmaceutica estable para uso oral. |
GB2356197A (en) | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
JP2001114736A (ja) | 1999-10-19 | 2001-04-24 | Kissei Pharmaceut Co Ltd | 2−アミノプロパノール誘導体 |
US6368628B1 (en) | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
GB0117618D0 (en) | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
DK1443917T3 (da) | 2001-11-07 | 2006-07-17 | Synthon Bv | Tamsulosintabletter |
US20030198619A1 (en) * | 2001-12-19 | 2003-10-23 | Dong Liang C. | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
WO2003092649A2 (en) | 2002-04-29 | 2003-11-13 | Alza Corporation | Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation |
EP1559427B1 (en) | 2002-11-07 | 2011-03-09 | Astellas Pharma Inc. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
EP1424079A1 (en) | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
JP2005162736A (ja) | 2003-11-10 | 2005-06-23 | Astellas Pharma Inc | 徐放性医薬組成物 |
JP2005162737A (ja) | 2003-11-10 | 2005-06-23 | Astellas Pharma Inc | 徐放性医薬組成物 |
US8128958B2 (en) * | 2003-11-10 | 2012-03-06 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
US8197846B2 (en) | 2003-11-10 | 2012-06-12 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
US20050287185A1 (en) | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
AU2006222409A1 (en) * | 2005-03-08 | 2006-09-14 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising sirolimus and/or an analogue thereof |
WO2007080776A1 (ja) | 2006-01-10 | 2007-07-19 | Kissei Pharmaceutical Co., Ltd. | 徐放性製剤およびその製造方法 |
WO2008084698A1 (ja) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | タクロリムス徐放性医薬組成物 |
WO2009019599A2 (en) | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
WO2009052353A2 (en) | 2007-10-17 | 2009-04-23 | Dr. Reddy's Laboratories Ltd. | Trospium pharmaceutical formulations |
TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
ES2665467T3 (es) | 2010-03-29 | 2018-04-25 | Astellas Pharma Inc. | Composición farmacéutica de liberación modificada |
WO2011122523A1 (ja) | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 放出制御医薬組成物 |
WO2012047530A1 (en) | 2010-09-28 | 2012-04-12 | International Business Machines Corporation | Providing answers to questions using logical synthesis of candidate answers |
-
2009
- 2009-09-25 TW TW098132502A patent/TWI478712B/zh active
- 2009-09-28 CA CA2740342A patent/CA2740342C/en active Active
- 2009-09-28 WO PCT/JP2009/066742 patent/WO2010038690A1/ja active Application Filing
- 2009-09-28 EP EP09817723.1A patent/EP2345410B1/en active Active
- 2009-09-28 CN CN201510642287.2A patent/CN105232448A/zh active Pending
- 2009-09-28 AU AU2009300752A patent/AU2009300752C1/en active Active
- 2009-09-28 HU HUE09817723A patent/HUE052874T2/hu unknown
- 2009-09-28 BR BRPI0919466-5A patent/BRPI0919466B1/pt not_active IP Right Cessation
- 2009-09-28 MX MX2011003445A patent/MX351855B/es active IP Right Grant
- 2009-09-28 PL PL09817723T patent/PL2345410T3/pl unknown
- 2009-09-28 JP JP2010531838A patent/JP4688089B2/ja active Active
- 2009-09-28 US US12/568,313 patent/US20160184275A2/en not_active Abandoned
- 2009-09-28 RU RU2011117274/15A patent/RU2495666C2/ru active
- 2009-09-28 PT PT98177231T patent/PT2345410T/pt unknown
- 2009-09-28 LT LTEP09817723.1T patent/LT2345410T/lt unknown
- 2009-09-28 CN CN2009801386919A patent/CN102170878A/zh active Pending
- 2009-09-28 EP EP20212426.9A patent/EP3827826A1/en active Pending
- 2009-09-28 DK DK09817723.1T patent/DK2345410T3/da active
- 2009-09-28 KR KR1020117009897A patent/KR101524164B1/ko active IP Right Review Request
- 2009-09-28 SI SI200932110T patent/SI2345410T1/sl unknown
- 2009-09-28 ES ES09817723T patent/ES2847876T3/es active Active
-
2010
- 2010-12-13 JP JP2010276634A patent/JP5625855B2/ja active Active
-
2011
- 2011-03-30 IL IL212033A patent/IL212033A/en active IP Right Grant
- 2011-03-31 ZA ZA2011/02406A patent/ZA201102406B/en unknown
-
2016
- 2016-04-13 HK HK16104217.1A patent/HK1216232A1/zh unknown
-
2017
- 2017-02-14 US US15/432,854 patent/US10842780B2/en active Active
-
2020
- 2020-11-19 US US16/952,795 patent/US20210322387A1/en not_active Abandoned
-
2021
- 2021-01-18 CY CY20211100034T patent/CY1123724T1/el unknown
- 2021-02-02 HR HRP20210179TT patent/HRP20210179T1/hr unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190117072A (ko) | 2018-04-06 | 2019-10-16 | 한미약품 주식회사 | 미라베그론이 함유된 방출 제어 약학적 조성물 |
KR20200043715A (ko) | 2018-10-18 | 2020-04-28 | 한미약품 주식회사 | 미라베그론이 함유된 방출 제어 약제학적 조성물 |
KR20210001710A (ko) | 2019-06-28 | 2021-01-06 | 한미약품 주식회사 | 제어 방출형 미라베그론 제제 및 이의 제조방법 |
KR20210112240A (ko) * | 2020-03-03 | 2021-09-14 | 동광제약 주식회사 | 미라베그론을 포함하는 제어 방출 제제 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210322387A1 (en) | Pharmaceutical composition for modified release | |
KR101647842B1 (ko) | 저장 안정성이 개선된 의약 조성물 | |
EP1849830B1 (en) | Finely divided composition containing poorly water soluble substance | |
EP2588086B1 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate. | |
EP2891493A1 (en) | Orally administered medical composition | |
EP2209501B1 (en) | Zibotentan composition containing mannitol and microcrystalline cellulose | |
EP3120871B1 (en) | Solid dispersion | |
KR101937713B1 (ko) | 약제학적 제제 및 그 제조방법 | |
KR20090092288A (ko) | 뉴로키닌 길항제를 포함하는 제약 제형 | |
TW201609195A (zh) | 固體抗病毒劑型 | |
JP6093762B2 (ja) | 徐放性製剤 | |
JP6123795B2 (ja) | 放出制御医薬組成物 | |
US20080182908A1 (en) | Pharmaceutical compositions comprising memantine | |
KR20110071104A (ko) | 경구 투여용 의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20180417 Year of fee payment: 4 |
|
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20190417 Year of fee payment: 5 |
|
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100000361; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170208 Effective date: 20200120 Free format text: TRIAL NUMBER: 2017100000369; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170209 Effective date: 20200120 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100000472; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170221 Effective date: 20200123 |
|
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100000530; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170222 Effective date: 20200213 Free format text: TRIAL NUMBER: 2018100000784; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180316 Effective date: 20200213 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100000567; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170222 Effective date: 20200219 Free format text: TRIAL NUMBER: 2017100000600; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170223 Effective date: 20200219 |